Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity

Pediatric Research

Volumn 79, Issue 1, 2016, Pages 70-75

  Hellgren, Gunnel ^a   Löfqvist, Chatarina ^a   Hård, Anna Lena ^a   Hansen Pupp, Ingrid ^b   Gram, Magnus ^b   Ley, David ^b   Smith, Lois E ^c   Hellström, Ann ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; BIRTH WEIGHT; BLOOD SAMPLING; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; PREMATURITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROLENTAL FIBROPLASIA; BLOOD; CHEMISTRY; COMORBIDITY; FETUS BLOOD; NEWBORN; NEWBORN DISEASE; PILOT STUDY; PROSPECTIVE STUDY; RETINOPATHY OF PREMATURITY;

COMORBIDITY; FEMALE; FETAL BLOOD; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFANT, PREMATURE; LASER THERAPY; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84955612175     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2015.181     Document Type: Article

References (25)

1. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000;41:1217-28.
2. Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology 2015;122:200-10.
3. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med 2012;367:2515-26.
4. Smith LE. Trough the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci 2008;49:5177-82.
5. Werdich XQ, McCollum G W, Rajaratnam VS, Penn JS. Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res 2004;79:623-30.
6. Austeng D, Källen KB, Hellström A, Tornqvist K, Holmström GE. Natural history of retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden. Arch Ophthalmol 2010;128:1289-94.
7. Pierce EA, Avery RL, Foley ED, Aiello L P, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92:905-9.
8. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101-11.
9. Galazios G, Papazoglou D, Giagloglou K, Vassaras G, Koutlaki N, Maltezos E. Umbilical cord serum vascular endothelial growth factor (VEGF) levels in normal pregnancies and in pregnancies complicated by preterm delivery or pre-eclampsia. Int J Gynaecol Obstet 2004;85:6-11.
10. Woo SJ, Park KH, Lee SY, et al. The relationship between cord blood cytokine levels and perinatal factors and retinopathy of prematurity: a gestational age-matched case-control study. Invest Ophthalmol Vis Sci 2013;54:3434-9.
11. Pieh C, Agostini H, Buschbeck C, et al. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol 2008;92:689-93.
12. Malamitsi-Puchner A, Tziotis J, Tsonou A, Protonotariou E, Saranda-kou A, Creatsas G. Changes in serum levels of vascular endothelial growth factor in males and females throughout life. J Soc Gynecol Investig 2000;7: 309-12.
13. Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology 2009;116:2165-9.
14. Sonmez K, Drenser KA, Capone A Jr, Trese MT. Vitreous levels of stro-mal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008;115: 1065-1070.e1.
15. Ma J, Mehta M, Lam G, et al. Influence of subretinal fuid in advanced stage retinopathy of prematurity on proangiogenic response and cell proliferation. Mol Vis 2014;20:881-93.
16. Kong L, Bhatt AR, Demny AB, et al. Pharmacokinetics of bevacizumab and its efects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 2015;56:956-61.
17. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopa-thy of prematurity. Am J Ophthalmol 2012;153:327-333.e1.
18. Yalin Imamoglu E, Gunay M, Gursoy T, et al. Efect of laser photocoagu-lation on plasma levels of VEGF-A, VEGFR-2, and Tie2 in infants with retinopathy of prematurity. J AAPOS 2014;18:466-70.
19. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pedi-atr Res 1994;36:724-31.
20. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthal-mol 1996;114:1219-28.
21. Budd SJ, Hartnett ME. Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity. Arch Ophthalmol 2010;128: 589-95.
22. Hansen-Pupp I, Löfqvist C, Polberger S, et al. Influence of insulin-like growth factor I and nutrition during phases of postnatal growth in very preterm infants. Pediatr Res 2011;69:448-53.
23. Marsál K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Pae-diatr 1996;85:843-8.
24. An international classifcation of retinopathy of prematurity. The committee for the classifcation of retinopathy of prematurity. Arch Ophthalmol 1984;102:1130-4.
25. Good W V, Hardy RJ, Dobson V, et al.; Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: fndings from the early treatment for retinopathy of prematurity study. Pediatrics 2005;116:15-23.